individuals differ: Viibryd gives you dosing options
Expand your dosing options with 2 effective dosage strengths
- The 20 mg therapeutic dose can be reached in 8 days1
Tablets shown are not actual size.
†Based on individual patient efficacy and tolerability, the dose may be increased up to 40 mg once daily with food after a minimum of 7 days between dosage increases.1
Viibryd® should be taken with food1
- Taking Viibryd on an empty stomach can reduce plasma concentrations (AUC) by approximately 50% and may diminish effectiveness
- If a dose is missed, it should be taken as soon as the patient remembers. If it is almost time for the next dose, the patient should skip the missed dose and take the next dose at the regular time. Two doses should not be taken at the same time.
- Prior to initiating treatment with Viibryd, screen patients for a personal or family history of bipolar disorder, mania, or hypomania.
- Adverse reactions may occur upon discontinuation of Viibryd. Gradual dose reduction rather than abrupt cessation is recommended whenever possible. Viibryd should be tapered from the 40 mg once daily dose to 20 mg once daily for 4 days, followed by 10 mg once daily for 3 days. Patients taking Viibryd 20 mg once daily should be tapered to 10 mg once daily for 7 days.
No dose adjustment is recommended for a range of populations1
- No dose adjustment necessary based on age or gender1
- No dose adjustment necessary for patients with renal impairment1
- No dose adjustment necessary for patients with hepatic impairment1
- The Viibryd dose should not exceed 20 mg once daily if co-administered with strong CYP3A4 inhibitors (eg, itraconazole, clarithromycin, voriconazole). The original Viibryd dose level can be resumed when the CYP3A4 inhibitor is discontinued.
- Based on clinical response, consider increasing Viibryd dose by 2-fold (up to a maximum 80 mg once daily) over 1 to 2 weeks when taking strong CYP3A4 inducers (eg, carbamazepine, phenytoin, rifampin) for greater than 14 days. If CYP3A4 inducers are discontinued, gradually reduce Viibryd dose to original level over 1 to 2 weeks.
- At least 14 days must elapse between discontinuation of an MAOI antidepressant and initiation of Viibryd. In addition, at least 14 days must elapse after stopping Viibryd before starting an MAOI antidepressant.
- Do not start Viibryd in a patient who is being treated with linezolid or intravenous methylene blue because there is an increased risk of serotonin syndrome.
- Concomitant use of Viibryd with NSAIDs, aspirin, warfarin, and other anticoagulants may increase the risk of bleeding events.
- Concomitant use of Viibryd increased digoxin concentrations. Measure serum digoxin concentrations before initiating concomitant use of Viibryd. Continue monitoring and reduce digoxin dose as necessary.
Use in Specific Populations
- There are no adequate and well-controlled studies of Viibryd in pregnant women. Consider the risks of untreated depression when discontinuing or changing treatment with antidepressant medication during pregnancy and postpartum.
- Exposure to SSRIs and SNRIs, including Viibryd, in late pregnancy may lead to an increased risk for neonatal complications requiring prolonged hospitalization, respiratory support, and tube feeding, and/or persistent pulmonary hypertension of the newborn (PPHN). Monitor neonates who were exposed to Viibryd in the third trimester of pregnancy for PPHN and drug discontinuation syndrome.
- There are no data on the presence of vilazodone in human milk, the effects of vilazodone on the breastfed infant, or the effects of the drug on milk production. However, vilazodone is excreted in rat milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Viibryd and any potential adverse effects on the breastfed child from Viibryd or from the underlying maternal condition.
- VIIBRYD (vilazodone HCl) [package insert]. Irvine, CA: Allergan USA, Inc.